adaptive radiotherapy: MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Study summary
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥18 years old;
2. High-grade glioma was confirmed by pathology after surgery;
3. ECOG score 0-2 points;
4. Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
5. Baseline data available.
Exclusion Criteria:
1. The pathological diagnosis is not clear;
2. No synchronous chemotherapy/adjuvant chemotherapy \< 6 cycles;
3. There are other malignant tumors;
4. Previously radiotherapy to the head;
5. Interruption of radiotherapy for more than 5 days;
6. Failure to collect baseline data.
Primary outcome measure(s)
Homogeneity index — up to 2 weeks HI: Homogeneity index. Dosimetric change
conformity index — up to 2 weeks CI: conformity index. Dosimetric change
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.